Page 226 - Drug Class Review
P. 226

Page 143 of 205
             Drug Effectiveness Review Project




























































                          Alzheimer Drugs   Authors: Whitehead et al. 33    Year: 2004  Medical Research Council  Study design: Meta-analysis (individual patient data)  Number of patients: 2,376  To evaluate the efficacy and tolerability of DON (5 and 10 mg/d) compared with placebo in alleviating  manifestations of mild to moderate AD  Published and unpublished data of 10 RCTs   Up to 1999  All randomized, double-blind, placebo-controlled, parallel-group studies from the DON clinical  development program undertaken and completed as of 20 December 1999, in which DON was administered  for more than one day at 5 and 10 mg/d  Pa

























             Final Report Update 1     Efficacy/Effectiveness      STUDY:      FUNDING:      DESIGN:          AIMS OF REVIEW:   STUDIES INCLUDED IN   META-ANALYSIS     TIME PERIOD COVERED:     CHARACTERISTICS OF  INCLUDED STUDIES:     CHARACTERISTICS OF  INCLUDED POPULATIONS:           Alzheimer's Drugs
   221   222   223   224   225   226   227   228   229   230   231